ORIC Pharmaceuticals (ORIC) just released detailed Phase 1b data for its prostate cancer drug candidate rinzimetostat with darolutamide, and selected a 400 mg daily dose for a planned global Phase 3 Himalayas 1 trial.
See our latest analysis for ORIC Pharmaceuticals.
The latest clinical update has come during a volatile stretch for ORIC, with a 1 day share price return of 18.93% following a 7 day share price return decline of 26.29% and a 30 day share price return decline of 35.16%. The 1 year total shareholder return of 82.17% and 3 year total shareholder return of 53.54% point to stronger longer term momentum despite pullbacks.
If you are curious about where else clinical progress is stirring interest in the market, this is a good moment to look beyond ORIC and scan 36 healthcare AI stocks
With ORIC at $8.89 and analysts on average targeting $21.00, the stock trades at a steep implied discount. This raises a key question for you: is this a genuine mispricing, or is future growth already reflected in expectations?
DCF says one thing, the market another: is the gap too wide to ignore?
On Simply Wall St's DCF model, ORIC's fair value sits at $43.32, compared with the last close of $8.89, which implies a very wide gap between modeled value and market price.
The DCF model takes projected future cash flows and discounts them back to today, aiming to capture what those future streams could be worth in present dollar terms. For a clinical stage biotech with no current revenue and a reported net loss of $129.47m, this kind of model leans heavily on assumptions around clinical success, timelines and eventual commercialization outcomes.
That context matters, because ORIC currently makes less than $1m in revenue, is unprofitable, and is not forecast to achieve profitability over the next 3 years. In situations like this, DCF outputs can swing a lot as inputs shift, so the modeled $43.32 should be seen as a reference point for expectations rather than a fixed anchor.
Look into how the SWS DCF model arrives at its fair value.
Result: DCF Fair value of $43.32 (UNDERVALUED)
However, the Himalayas 1 plan still hinges on clinical outcomes and ORIC's ability to fund ongoing net losses of $129.47m with a market cap under $1b.
Find out about the key risks to this ORIC Pharmaceuticals narrative.
Another angle on valuation: book value sends a different signal
While the SWS DCF model points to a large gap between price and modeled fair value, the P/B ratio tells a more cautious story. ORIC trades at 2.3x book value, slightly above the US Biotechs industry average of 2.2x, yet well below the 4.7x peer average. This suggests mixed signals on how generous the market is being today.
With no meaningful revenue, ongoing losses and a P/B that sits between industry and peers, book value does not clearly indicate either a bargain or a bubble. This raises the question of how much weight to place on this metric compared with the cash flow view.
See what the numbers say about this price — find out in our valuation breakdown.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ORIC Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Given all these mixed signals, does the story feel clear to you yet, or still a bit unsettled? Move quickly, review the details for yourself, and weigh both the possible upside and the clinical and funding risks by checking out the 1 key reward and 5 important warning signs
Looking for more investment ideas?
If ORIC has your attention but you want a broader watchlist, now is the time to widen your search and compare other opportunities side by side.
- Target potential mispricing by scanning companies that combine quality fundamentals with attractive valuations using the 58 high quality undervalued stocks.
- Prioritize resilience by reviewing the 68 resilient stocks with low risk scores and see which companies stand out for lower overall risk scores.
- Get ahead of the crowd by using the screener containing 25 high quality undiscovered gems to spot lesser known names backed by solid fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com